Phenotypes associated with this allele

• Allele Symbol: Grk5^tm1Rjl
• Allele Name: targeted mutation 1, Robert J Lefkowitz
• Allele ID: MGI:2383968
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Grk5^tm1Rjl/Grk5^tm1Rjl	involves: 129S4/SvJaeSor	MGI:5582622
hm2	Grk5^tm1Rjl/Grk5^tm1Rjl	involves: 129S4/SvJaeSor * C57BL/6	MGI:3639521

Genotype
MGI:5582622

hm1

• Allelic Composition: Grk5^tm1Rjl/Grk5^tm1Rjl
• Genetic Background: involves: 129S4/SvJaeSor

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cardiovascular system

cardiac hypertrophy ( J:212635 )

• 12 weeks after transaortic constriction, mice exhibit delayed and reduced cardiac hypertrophy compared with wild-type mice

• mice are resistant to phenylephrine-dependent hypertrophy compared with wild-type mice

decreased response of heart to induced stress ( J:212635 )

• 12 weeks after transaortic constriction, mice exhibit attenuated pressure-overload-induced cardiac growth with delayed and reduced cardiac hypertrophy and no sign of left ventricular dilatation and preserved cardiac function compared with wild-type mice

• mice are resistant to phenylephrine-dependent hypertrophy compared with wild-type mice

homeostasis/metabolism

decreased response of heart to induced stress ( J:212635 )

• 12 weeks after transaortic constriction, mice exhibit attenuated pressure-overload-induced cardiac growth with delayed and reduced cardiac hypertrophy and no sign of left ventricular dilatation and preserved cardiac function compared with wild-type mice

• mice are resistant to phenylephrine-dependent hypertrophy compared with wild-type mice

growth/size/body

cardiac hypertrophy ( J:212635 )

• 12 weeks after transaortic constriction, mice exhibit delayed and reduced cardiac hypertrophy compared with wild-type mice

• mice are resistant to phenylephrine-dependent hypertrophy compared with wild-type mice

Genotype
MGI:3639521

hm2

• Allelic Composition: Grk5^tm1Rjl/Grk5^tm1Rjl
• Genetic Background: involves: 129S4/SvJaeSor * C57BL/6

homeostasis/metabolism

increased salivation ( J:59179 )

• in response to muscarinic agonists (oxotremorine)

decreased body temperature ( J:59179 )

• greater and longer lasting body temperature depression in response to muscarinic agonists (oxotremorine)

decreased core body temperature ( J:59179 )

• core body temperature is about 0.9^oC lower than controls

behavior/neurological

tremors ( J:59179 )

• increased and prolonged tremors in response to muscarinic agonists (oxotremorine)

decreased locomotor activity ( J:59179 )

• greater and longer lasting depression of horizontal activity in response to muscarinic agonists (oxotremorine)

decreased thermal nociceptive threshold ( J:59179 )

• respond less in a hot plate test after application of muscarinic agonists (oxotremorine)

• effect of oxotremorine is longer lasting and noticeable at lower doses than in controls

nervous system

abnormal CNS synaptic transmission ( J:59179 )

• muscarinic receptors in the brain stem are resistant to desensitization

digestive/alimentary system

increased salivation ( J:59179 )

• in response to muscarinic agonists (oxotremorine)

respiratory system

increased airway responsiveness ( J:96208 )

• tracheal airway hyperresponsive to vagal stimulation as measured by airway pressure time index (APTI)

muscle

abnormal muscle contractility ( J:96208 )

• M2 receptors of smooth muscle in the tracheal airway are desensitized

endocrine/exocrine glands

increased salivation ( J:59179 )

• in response to muscarinic agonists (oxotremorine)